IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Mesenchymal stem cells (MSC) from BM of chronic myeloid leukaemia (CML) patients on interaction with CML cells or its secreted factors, secreted high levels of IL6, providing a survival advantage to CML cells from imatinib-induced apoptosis [35]; Thus, IL6 may contribute to CML immune escape.